title: In defense of organ sharing in kidney transplantation.
abstract: 1. The risks associated with nonbeneficial matching constitute a persistent hazard to the transplant over a long period. 2. The benefits of HLA matching and CsA are separate and additive. 3. There is no evidence that beneficial matching is not relevant to all (UK) centers. 4. Contemporary typing methods are expected to improve the accuracy of typing and reduce kidney cold-ischemia times. 5. Organ sharing increases the numbers of beneficial matches. 6. Patients with easily matchable ABO-HLA phenotypes should wait for beneficially matched transplants. 7. Patients with phenotypes that are difficult to match should be intelligently mismatched after due consideration of responder status, acceptable mismatches, and cross-reactive groups. 8. Organ sharing does not prejudice graft survival. 9. Wastage is minimized with a central clearing house. 10. Organ sharing reduces the incidence of high sensitization. 11. Organ sharing is cost effective. For these reasons we repudiate the view that organ sharing is now superfluous.
authors.affiliation: United Kingdom Transplant Service, England.
authors.forename: B A
authors.initials: BA
authors.lastname: Bradley
authors.forename: W R
authors.initials: WR
authors.lastname: Gilks
authors.forename: S M
authors.initials: SM
authors.lastname: Gore
authors.forename: P T
authors.initials: PT
authors.lastname: Klouda
authors.forename: N H
authors.initials: NH
authors.lastname: Selwood
authors.forename: T C
authors.initials: TC
authors.lastname: Ray
mesh_terms: D003524:Cyclosporins / Q000627:therapeutic use; D006085:Graft Survival; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D009927:Tissue and Organ Procurement
chemical_list: D003524:Cyclosporins; D006680:HLA Antigens